CXCL10 and dermatomyositis: Both biomarkers distinguished between active disease and remission in the adult DM cohort (P = 0.0126 and P < 0.0001 for galectin‐9 and CXCL10, respectively), and CXCL10 was also discriminative for disease activity in patients with NSM (P = 0.0139) and those with EF (P = 0.0497) (Figures 2A and B).